drugset / Trial / NCT00144495
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effectiveness and safety of recombinant human erythropoietin in anemic cancer patients undergoing chemotherapy.
Timeline
- Start
- 2004-02
- Primary completion
- 2004-11
- Completion
- 2005-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | 36000 iu | Subcutaneous |
| Subject | epoetin alfa | Protein / enzyme biologic | 54000 iu | Subcutaneous |